# Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

> **NCT02634827** · PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Acute Myeloid Leukemia With Gene Mutations
- FLT3 Tyrosine Kinase Domain Point Mutation
- Secondary Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Midostaurin

## Key facts

- **NCT ID:** NCT02634827
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-30
- **Primary completion:** 2017-03-18
- **Final completion:** 2018-06-12
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2019-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634827, "Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02634827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*